NEW YORK (GenomeWeb) – OncoCyte said today that it has applied for CLIA lab certification, moving it closer to the objective of launching a lung cancer diagnostic test — its first commercial product — in the second half of 2017.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.